Method for apparent editing of target spot and application

CN119698469APending Publication Date: 2025-03-25EPIGENIC THERAPEUTICS PTE LTD
0 Cites 0 Cited by

Patent Information

Application Number
CN202380058898.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-08-11
Filing Date
2023-08-10
Publication Date
2025-03-25

AI Technical Summary

Technical Problem

Existing epigenetic editing technologies have challenges such as safety, toxicity, immunogenicity, and off-target effects in the in vivo environment, making it difficult to effectively regulate target gene expression and reduce toxicity and immunogenicity.

Method used

A gene expression regulatory molecule containing a DNA methyltransferase and a zinc finger protein-based transcription factor or histone modification enzyme is used to modify the nucleotide by targeting the vicinity of the LPA gene or regulatory elements to regulate the expression of the target gene. The DNA binding domain of the CRISPR/Cas system ensures targeting and efficiency.

Benefits of technology

It improves the safety and efficiency of epigenetic editing, reduces toxicity and immunogenicity, achieves precise regulation of LPA gene expression, and alleviates diseases related to LPA gene abnormalities.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A method of modulating the expression level of a target gene and a nucleic acid binding molecule are provided, the combination of the nucleic acid binding molecule and a gene expression modulating molecule having the ability to modulate the expression level of the target gene.
Need to check novelty before this filing date? Find Prior Art